Wefunder logo

Squarex, LLC

Preventing oral herpes with a topical application to the arm

Last Funded March 2022

$235,067

raised from 173 investors
Pitch Video
Investor Panel

Investor Panel

Shu interviewed Squarex, LLC on July 19, 2021. Play Video
Shu Li
CEO and co-founder of Petri-Bio
Strengths
says, "Cold Sore is such a common problem but there're not many good solution for it. I'm glad this company found the solution that is working"
Advice
says, "I'm from the biotech industry so I know how big an achievement it is to get good data from all the clinical trial phases. I'd like to emphasize that and make sure all the investors can know this"
Comment from Squarex, LLC

Squarex, LLC says, "Thank you. We are proud that we have had significant efficacy in 3 of 3 clinical trials. With cold sores affecting around 30-40 million people in the U.S. alone, we look forward to bringing help soon by getting this to market. We appreciate the Wefunder investors helping us to bring this relief to cold sore sufferers as soon as possible."

What Investors Say

LEAD INVESTOR
Invested $25,000 this round
I’m investing in Squarex because it is solving a big problem in cold sores or oral herpes, and this represents a huge market and profit opportunity as well. Millions of people in the U.S. alone have frequent cold sores and will be eager to get this drug. No other drug is approved for preventing cold sore outbreaks, and prevention is better than treatment. It goes without saying that a drug that works for oral herpes is likely to work for genital herpes as well, and that is another huge market and huge human problem. They have come a long way in their trials, two-thirds of the way to FDA approval, with a small amount of money in the context of the pharmaceutical world, and the drug has repeatedly proven very effective in human clinical trials, including trials at Harvard and Stanford. In addition, my spouse happens to know and respect the founder and CEO of Squarex.
What People Say